MedTrace Logo

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

NCT05613296 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2025-04-30

No results posted yet for this study

Summary

This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.

Conditions

  • ITP - Immune Thrombocytopenia
  • Chronic ITP
  • Refractory ITP

Interventions

DRUG

Fostamatinib

Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Francesco Zaja · Ematologia ASUGI Trieste

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05613296 on ClinicalTrials.gov